These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17269585)

  • 1. Is raloxifene ready to be used for prevention of breast cancer?
    Powles TJ
    Int J Fertil Womens Med; 2006; 51(5):203-4. PubMed ID: 17269585
    [No Abstract]   [Full Text] [Related]  

  • 2. Defining the role of raloxifene for the prevention of breast cancer.
    Kalidas M; Hilsenbeck S; Brown P
    J Natl Cancer Inst; 2004 Dec; 96(23):1731-3. PubMed ID: 15572750
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevention of breast cancer using selective oestrogen receptor modulators (SERMs).
    Powles TJ
    Breast Cancer Res; 2006; 8(5):111. PubMed ID: 17049068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raloxifene (Evista) for breast cancer prevention in postmenopausal women.
    Med Lett Drugs Ther; 2006 May; 48(1234):37. PubMed ID: 16685245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective estrogen-receptor modulators for primary prevention of breast cancer.
    Fabian CJ; Kimler BF
    J Clin Oncol; 2005 Mar; 23(8):1644-55. PubMed ID: 15755972
    [No Abstract]   [Full Text] [Related]  

  • 7. Task force cautious about chemoprevention. Official guidelines are out about taking tamoxifen and raloxifene to prevent breast cancer. These drugs can help, but they aren't for everyone.
    Harv Womens Health Watch; 2002 Oct; 10(2):1-2. PubMed ID: 12393316
    [No Abstract]   [Full Text] [Related]  

  • 8. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moving forward with breast cancer prevention.
    Chen WY; Rosner B; Colditz GA
    Cancer; 2007 Jun; 109(12):2387-91. PubMed ID: 17464950
    [No Abstract]   [Full Text] [Related]  

  • 10. Experts hopeful about designer estrogens. For some women, selective estrogen receptor modulators (SERMs) help prevent breast cancer.
    Runowicz CD
    Health News; 2003 Apr; 9(4):1-2. PubMed ID: 12710388
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
    Higuchi T; Mizunuma H
    Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial.
    Jordan VC
    Eur J Cancer; 2006 Nov; 42(17):2909-13. PubMed ID: 17064889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Selective estrogen receptor modulator].
    Ohta H
    Clin Calcium; 2004 Jan; 14(1):165-72. PubMed ID: 15576973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone builder vs. breast cancer.
    Johns Hopkins Med Lett Health After 50; 2007 Jan; 18(11):1-2. PubMed ID: 17323491
    [No Abstract]   [Full Text] [Related]  

  • 16. Raloxifene works as well as tamoxifen in preventing invasive breast cancer.
    Mayo Clin Womens Healthsource; 2006 Oct; 10(10):3. PubMed ID: 16977270
    [No Abstract]   [Full Text] [Related]  

  • 17. [Where do SERMs stand in the light of clinical application?].
    Takeuchi Y
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():306-10. PubMed ID: 18159712
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term raloxifene in a woman at high risk for breast cancer.
    Bean GR; Kimler BF; Seewaldt VL
    N Engl J Med; 2006 Oct; 355(15):1620-2. PubMed ID: 17035661
    [No Abstract]   [Full Text] [Related]  

  • 19. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The rise of raloxifene and the fall of invasive breast cancer.
    Jordan VC
    J Natl Cancer Inst; 2008 Jun; 100(12):831-3. PubMed ID: 18544739
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.